Paper41301083
Niclosamide and Palbociclib Act Synergistically to Reduce Cholangiocarcinoma Cell Viability In Vitro and Inhibit Tumour Growth in a Mouse Model.
Martin G and 9 others. Cancers (Basel), 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Niclosamide and Palbociclib Act Synergistically to Reduce Cholangiocarcinoma Cell Viability In Vitro and Inhibit Tumour Growth in a Mouse Model. Papers, record 41301083. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41301083
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Niclosamide and Palbociclib Act Synergistically to Reduce Cholangiocarcinoma Cell Viability In Vitro and Inhibit Tumour Growth in a Mouse Model.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| MR/N012615/1 | UK Medical Research Council | PubMed | ||
| 2019/204 | AMMF | PubMed |
Source PubMed
References44
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32416072 | Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. | Lancet Oncol | 2020 | https://conductscience.org/library/papers/32416072 | PubMed |
| 2 | 32606456 | Cholangiocarcinoma 2020: the next horizon in mechanisms and management. | Nat Rev Gastroenterol Hepatol | 2020 | https://conductscience.org/library/papers/32606456 | PubMed |
| 3 | 38357420 | Cholangiocarcinoma across England: Temporal changes in incidence, survival and routes to diagnosis by region and level of socioeconomic deprivation. | JHEP Rep | 2024 | https://conductscience.org/library/papers/38357420 | PubMed |
| 4 | 28877265 | Niclosamide induces protein ubiquitination and inhibits multiple pro-survival signaling pathways in the human glioblastoma U-87 MG cell line. | PLoS One | 2017 | https://conductscience.org/library/papers/28877265 | PubMed |
| 5 | 30258081 | Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. | Nat Commun | 2018 | https://conductscience.org/library/papers/30258081 | PubMed |
| 6 | 31843982 | A Runaway PRH/HHEX-Notch3-Positive Feedback Loop Drives Cholangiocarcinoma and Determines Response to CDK4/6 Inhibition. | Cancer Res | 2020 | https://conductscience.org/library/papers/31843982 | PubMed |
| 7 | 37917550 | Combination therapy of niclosamide with gemcitabine inhibited cell proliferation and apoptosis via Wnt/β-catenin/c-Myc signaling pathway by inducing β-catenin ubiquitination in pancreatic cancer. | Cancer Biol Ther | 2023 | https://conductscience.org/library/papers/37917550 | PubMed |
| 8 | 36765923 | CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36765923 | PubMed |
| 9 | 38838500 | An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202. | ESMO Open | 2024 | https://conductscience.org/library/papers/38838500 | PubMed |
| 10 | 19072826 | Hematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid-induced liver hypertrophy. | Hepatology | 2009 | https://conductscience.org/library/papers/19072826 | PubMed |
| 11 | 3196713 | Structural requirements of salicylanilides for uncoupling activity in mitochondria: quantitative analysis of structure-uncoupling relationships. | Biochim Biophys Acta | 1988 | https://conductscience.org/library/papers/3196713 | PubMed |
| 12 | 34504109 | Cholangiocarcinoma. | Nat Rev Dis Primers | 2021 | https://conductscience.org/library/papers/34504109 | PubMed |
| 13 | 36479072 | The magic bullet: Niclosamide. | Front Oncol | 2022 | https://conductscience.org/library/papers/36479072 | PubMed |
| 14 | 22829072 | Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production. | Blood Cancer J | 2011 | https://conductscience.org/library/papers/22829072 | PubMed |
| 15 | 17580084 | The homeobox gene Hhex is essential for proper hepatoblast differentiation and bile duct morphogenesis. | Dev Biol | 2007 | https://conductscience.org/library/papers/17580084 | PubMed |
| 16 | 32223935 | TRK inhibitors in TRK fusion-positive cancers. | Ann Oncol | 2019 | https://conductscience.org/library/papers/32223935 | PubMed |
| 17 | 1360645 | Identification of a novel vertebrate homeobox gene expressed in haematopoietic cells. | Nucleic Acids Res | 1992 | https://conductscience.org/library/papers/1360645 | PubMed |
| 18 | 32961231 | Niclosamide-loaded polymeric micelles ameliorate hepatocellular carcinoma in vivo through targeting Wnt and Notch pathways. | Life Sci | 2020 | https://conductscience.org/library/papers/32961231 | PubMed |
| 19 | 12826010 | The transcriptional repressor protein PRH interacts with the proteasome. | Biochem J | 2003 | https://conductscience.org/library/papers/12826010 | PubMed |
| 20 | 38025687 | Metabolomic analyses uncover an inhibitory effect of niclosamide on mitochondrial membrane potential in cholangiocarcinoma cells. | PeerJ | 2023 | https://conductscience.org/library/papers/38025687 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| HHEX | 3087 | PubTator's text mining | https://conductscience.org/library/genes/3087 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41301083
GET https://conductscience.org/api/papers/v1/41301083/references?page=2